JP2020513404A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513404A5 JP2020513404A5 JP2019529476A JP2019529476A JP2020513404A5 JP 2020513404 A5 JP2020513404 A5 JP 2020513404A5 JP 2019529476 A JP2019529476 A JP 2019529476A JP 2019529476 A JP2019529476 A JP 2019529476A JP 2020513404 A5 JP2020513404 A5 JP 2020513404A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antagonist
- amino acid
- acid sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims 55
- 108010067003 Interleukin-33 Proteins 0.000 claims 53
- 102000017761 Interleukin-33 Human genes 0.000 claims 53
- 125000003275 alpha amino acid group Chemical group 0.000 claims 42
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 16
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 16
- 208000027866 inflammatory disease Diseases 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 11
- 102100036706 Interleukin-1 receptor-like 1 Human genes 0.000 claims 10
- 208000006673 asthma Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 102000005962 receptors Human genes 0.000 claims 7
- 108020003175 receptors Proteins 0.000 claims 7
- 102000004388 Interleukin-4 Human genes 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 229940028885 interleukin-4 Drugs 0.000 claims 6
- 210000004072 lung Anatomy 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 102100039880 Interleukin-1 receptor accessory protein Human genes 0.000 claims 5
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 5
- 230000003176 fibrotic effect Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 108010002616 Interleukin-5 Proteins 0.000 claims 3
- 102000000743 Interleukin-5 Human genes 0.000 claims 3
- 102000004889 Interleukin-6 Human genes 0.000 claims 3
- 108090001005 Interleukin-6 Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000003979 eosinophil Anatomy 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 210000002216 heart Anatomy 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 229940100602 interleukin-5 Drugs 0.000 claims 3
- 229940100601 interleukin-6 Drugs 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 2
- 241000208125 Nicotiana Species 0.000 claims 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 238000003915 air pollution Methods 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 229950003468 dupilumab Drugs 0.000 claims 2
- 230000007613 environmental effect Effects 0.000 claims 2
- 239000003517 fume Substances 0.000 claims 2
- 239000002085 irritant Substances 0.000 claims 2
- 231100000021 irritant Toxicity 0.000 claims 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 239000000779 smoke Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 claims 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims 1
- 229930182837 (R)-adrenaline Natural products 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 108010006654 Bleomycin Proteins 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 101150020847 CCL11 gene Proteins 0.000 claims 1
- 101150052909 CCL2 gene Proteins 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 206010051841 Exposure to allergen Diseases 0.000 claims 1
- 101150019209 IL13 gene Proteins 0.000 claims 1
- 101150112813 IL13RA2 gene Proteins 0.000 claims 1
- 101150101999 IL6 gene Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 101150018215 Il1rl1 gene Proteins 0.000 claims 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 102000000589 Interleukin-1 Human genes 0.000 claims 1
- 102000003777 Interleukin-1 beta Human genes 0.000 claims 1
- 108090000193 Interleukin-1 beta Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 101100490443 Mus musculus Acvr1 gene Proteins 0.000 claims 1
- 101100328841 Mus musculus Col15a1 gene Proteins 0.000 claims 1
- 101100440642 Mus musculus Col24a1 gene Proteins 0.000 claims 1
- 101100179589 Mus musculus Il9 gene Proteins 0.000 claims 1
- 208000000592 Nasal Polyps Diseases 0.000 claims 1
- 206010068786 Overlap syndrome Diseases 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 101150000629 TGFB1 gene Proteins 0.000 claims 1
- 101150033527 TNF gene Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- -1 bronchial dilators Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 239000000850 decongestant Substances 0.000 claims 1
- 229940124581 decongestants Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 229960005139 epinephrine Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000002175 goblet cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 230000000527 lymphocytic effect Effects 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000000115 thoracic cavity Anatomy 0.000 claims 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 1
- 230000029069 type 2 immune response Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022132878A JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428634P | 2016-12-01 | 2016-12-01 | |
| US62/428,634 | 2016-12-01 | ||
| US201762473738P | 2017-03-20 | 2017-03-20 | |
| US62/473,738 | 2017-03-20 | ||
| US201762567318P | 2017-10-03 | 2017-10-03 | |
| US62/567,318 | 2017-10-03 | ||
| PCT/US2017/064041 WO2018102597A1 (en) | 2016-12-01 | 2017-11-30 | Methods of treating inflammatory conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132878A Division JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513404A JP2020513404A (ja) | 2020-05-14 |
| JP2020513404A5 true JP2020513404A5 (enExample) | 2021-01-07 |
| JP7132220B2 JP7132220B2 (ja) | 2022-09-06 |
Family
ID=60788696
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529476A Active JP7132220B2 (ja) | 2016-12-01 | 2017-11-30 | 炎症性状態の処置方法 |
| JP2022132878A Active JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A Pending JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022132878A Active JP7351989B2 (ja) | 2016-12-01 | 2022-08-24 | 炎症性状態の処置方法 |
| JP2023148026A Pending JP2023175785A (ja) | 2016-12-01 | 2023-09-13 | 炎症性状態の処置方法 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10815305B2 (enExample) |
| EP (1) | EP3548513A1 (enExample) |
| JP (3) | JP7132220B2 (enExample) |
| KR (3) | KR20250040088A (enExample) |
| CN (2) | CN110167963B (enExample) |
| AU (2) | AU2017367691B2 (enExample) |
| BR (1) | BR112019010646A2 (enExample) |
| CA (1) | CA3044851A1 (enExample) |
| CL (1) | CL2019001475A1 (enExample) |
| CO (1) | CO2019005236A2 (enExample) |
| CR (1) | CR20190311A (enExample) |
| IL (1) | IL266770B2 (enExample) |
| MA (1) | MA46954A (enExample) |
| MX (2) | MX2019006177A (enExample) |
| MY (1) | MY200433A (enExample) |
| NZ (1) | NZ754300A (enExample) |
| PH (1) | PH12019501120A1 (enExample) |
| TN (1) | TN2019000172A1 (enExample) |
| TW (2) | TWI784988B (enExample) |
| UA (1) | UA127965C2 (enExample) |
| WO (1) | WO2018102597A1 (enExample) |
| ZA (1) | ZA201903091B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2690675C2 (ru) | 2012-08-21 | 2019-06-05 | Санофи Байотекнолоджи | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |
| PL3448391T3 (pl) | 2016-04-27 | 2024-09-16 | AbbVie Manufacturing Management Unlimited Company | Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| MX2019012171A (es) | 2017-04-13 | 2019-11-25 | Regeneron Pharma | Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1. |
| CN118994394A (zh) | 2017-06-12 | 2024-11-22 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| KR20250044796A (ko) * | 2017-10-30 | 2025-04-01 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| JP2021508719A (ja) | 2017-12-29 | 2021-03-11 | コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | 好酸球性障害のための遺伝子療法 |
| CN111212862B (zh) | 2018-04-10 | 2023-11-14 | 株式会社力森诺科 | 环氧树脂、环氧树脂组合物、环氧树脂固化物和复合材料 |
| IL277890B2 (en) | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantifying il-33 |
| US11312778B2 (en) | 2018-11-21 | 2022-04-26 | Brian C. Machler | Method for treating allergic contact dermatitis |
| CN111494626B (zh) | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
| EP3911369A4 (en) | 2019-01-18 | 2022-11-16 | Orthobio Therapeutics, Inc. | GENE EDITING TO IMPROVE JOINT FUNCTION |
| TW202519263A (zh) | 2019-03-21 | 2025-05-16 | 美商再生元醫藥公司 | 含有抗il-33抗體之穩定調配物 |
| EP3962515A1 (en) * | 2019-05-01 | 2022-03-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| JP7592064B2 (ja) | 2019-07-16 | 2024-11-29 | サノフィ・バイオテクノロジー | Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 |
| WO2021068196A1 (en) * | 2019-10-11 | 2021-04-15 | General Regeneratives (Shanghai) Limited | Methods of using il-33 protein in treating cancers |
| WO2021089559A1 (en) * | 2019-11-04 | 2021-05-14 | Medimmune Limited | Anti il-33 therapeutic agent fpr treating renal disorders |
| MX2022006812A (es) * | 2019-12-06 | 2022-08-25 | Sanofi Biotechnology | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
| EP4081544A1 (en) * | 2019-12-23 | 2022-11-02 | Sanofi Biotechnology | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
| CN115315527A (zh) | 2020-03-13 | 2022-11-08 | 免疫医疗有限公司 | 用于治疗il33中存在风险等位基因的受试者的治疗方法 |
| IL296853A (en) * | 2020-04-06 | 2022-11-01 | Medimmune Ltd | Treatment of acute respiratory distress syndrome with il-33 axis binding antagonists |
| CN113527485B (zh) * | 2020-04-17 | 2024-11-15 | 湖南麦济生物技术股份有限公司 | 抗人白细胞介素-4受体α抗体及其制备方法和应用 |
| CN113549151A (zh) * | 2020-04-24 | 2021-10-26 | 苏州康乃德生物医药有限公司 | 与人IL-4Rα中特定表位结合的抗体及其应用 |
| JP7578943B2 (ja) * | 2020-07-13 | 2024-11-07 | 学校法人自治医科大学 | 褥瘡治療剤 |
| CN111714619B (zh) * | 2020-07-15 | 2023-03-14 | 上海市浦东新区人民医院 | 成纤维生长因子6在制备缓解非酒精性脂肪性肝炎肝损伤的药物中的应用 |
| IL303135A (en) * | 2020-12-23 | 2023-07-01 | Numab Therapeutics AG | Antibody variable domains that bind IL-4R |
| CN117858898A (zh) * | 2021-08-27 | 2024-04-09 | 免疫医疗有限公司 | 用抗白介素-33抗体治疗慢性阻塞性肺病 |
| US20230272096A1 (en) * | 2021-11-11 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Risk Score For Interleukin 33 (IL-33) |
| EP4614996A1 (en) | 2022-10-31 | 2025-09-10 | Toyota Jidosha Kabushiki Kaisha | Vehicle control system, vehicle manufacturing method, program, and information processing device |
| KR20250157410A (ko) * | 2023-02-28 | 2025-11-04 | 코디악 사이언시스 인코포레이티드 | 다가 트랩-항체 융합체 |
| CN120118185B (zh) * | 2025-03-11 | 2025-08-26 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | 一种猫过敏原Fel d 1蛋白单克隆抗体及其应用 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| EP0668774A1 (en) | 1991-05-03 | 1995-08-30 | Seragen, Inc. | Interleukin receptor targeted molecules for treatment of inflammatory arthritis |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5714146A (en) | 1992-08-26 | 1998-02-03 | Board Of Regents Of The University Of Washington | IL-4 bone therapy |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| RU2162711C2 (ru) | 1993-09-07 | 2001-02-10 | Смитклайн Бичам Корпорейшн | Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4 |
| US5576191A (en) | 1994-06-17 | 1996-11-19 | Immunex Corporation | Cytokine that binds ST2 |
| ES2259478T3 (es) | 1998-09-18 | 2006-10-01 | Dynavax Technologies Corporation | Metodos para tratar trastornos asociados con la ige y composiciones para este uso. |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| ES2382891T3 (es) | 2000-05-26 | 2012-06-14 | Immunex Corporation | Uso de anticuerpos IL-4R y sus composiciones |
| US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
| CA2446108A1 (en) | 2001-05-11 | 2002-11-21 | Novartis Ag | Compositions for use in treating ige-associated disorders |
| CA2447795A1 (en) | 2001-05-23 | 2002-11-28 | Duotol Ab | Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| PT1527100E (pt) | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
| AU2003299441A1 (en) | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
| AU2004209637A1 (en) | 2003-02-01 | 2004-08-19 | Tanox, Inc. | A method for generating high affinity antibodies |
| US7923209B2 (en) | 2003-03-14 | 2011-04-12 | Anergis, S.A. | Allergen peptide fragments and use thereof |
| CA2543982C (en) | 2003-11-07 | 2013-01-08 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| CA2550933A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Methods for identifying functional antibodies |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| ATE395358T1 (de) | 2004-02-27 | 2008-05-15 | Regeneron Pharma | Il-4/il-13-spezifische polypetide und deren therapeutische verwendung |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006083390A2 (en) | 2004-12-07 | 2006-08-10 | Children's Hospital Medical Center | Eotaxin-3 in eosinophilic esophagitis |
| TW200902555A (en) | 2005-01-03 | 2009-01-16 | Hoffmann La Roche | Antibodies against IL-13 receptor alpha 1 and uses thereof |
| EP2301969B1 (en) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
| US7666622B2 (en) | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| WO2007140205A2 (en) | 2006-05-24 | 2007-12-06 | Biogen Idec Ma Inc. | Methods of treating fibrosis |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| JP4221018B2 (ja) | 2006-08-31 | 2009-02-12 | トヨタ自動車株式会社 | 頭部保護エアバッグ装置 |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN101522716B (zh) | 2006-10-02 | 2013-03-20 | 瑞泽恩制药公司 | 抗人il-4受体的高亲和力人抗体 |
| WO2008132709A1 (en) | 2007-04-26 | 2008-11-06 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Products for altering il-33 activity and methods therefor |
| AU2008254704A1 (en) | 2007-05-18 | 2008-11-27 | Medimmune, Llc | IL-33 in inflammatory disease |
| EP2022507A1 (en) | 2007-08-07 | 2009-02-11 | Universität Hamburg | Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| WO2009053098A1 (en) | 2007-10-26 | 2009-04-30 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders |
| US8637239B2 (en) | 2007-11-05 | 2014-01-28 | The Board Of Trustees Of The University Of Illinois | Minimally-invasive measurement of esophageal inflammation |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| DE202008006598U1 (de) | 2008-04-11 | 2008-10-02 | Alk-Abelló A/S | Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| WO2010065557A2 (en) | 2008-12-01 | 2010-06-10 | Cincinnati Children's Hospital Medical Center | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis |
| US8497528B2 (en) | 2010-05-06 | 2013-07-30 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method for fabricating a strained structure |
| CN107320722A (zh) | 2009-09-07 | 2017-11-07 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| EP2475388B1 (en) | 2009-09-10 | 2017-11-08 | Merck Sharp & Dohme Corp. | Use of il-33 antagonists to treat fibrotic disease |
| EP2585075B8 (en) | 2010-06-24 | 2021-09-22 | ViroPharma Biologics LLC | Methods of treatment for esophageal inflammation |
| JP5918246B2 (ja) | 2010-10-06 | 2016-05-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗インターロイキン−４受容体（ｉｌ−４ｒ）抗体を含有する安定化製剤 |
| WO2012094643A2 (en) | 2011-01-06 | 2012-07-12 | Children's Hospital Medical Center | Esophageal cytokine expression profiles in eosinophilic esophagitis |
| TW201238976A (en) | 2011-02-23 | 2012-10-01 | Hoffmann La Roche | Antibodies against human IL33R and uses thereof |
| CA2840086A1 (en) | 2011-06-21 | 2012-12-27 | Children's Hospital Medical Center | Diagnostic methods for eosinophilic esophagitis |
| WO2013051928A1 (en) | 2011-10-06 | 2013-04-11 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
| WO2013155010A1 (en) | 2012-04-09 | 2013-10-17 | Children's Hospital Medical Center | Non-invasive biomarkers for eosinophilic esophagitis |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| RU2690675C2 (ru) * | 2012-08-21 | 2019-06-05 | Санофи Байотекнолоджи | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| WO2014059178A1 (en) | 2012-10-10 | 2014-04-17 | Rhode Island Hospital | Differential expression of novel protein markers for the diagnosis and treatment of eosinophilic esophagitis |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MX364591B (es) * | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| TWI697334B (zh) | 2013-06-04 | 2020-07-01 | 美商再生元醫藥公司 | 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EP3613432B1 (en) * | 2013-06-21 | 2025-08-06 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| TWI563003B (en) | 2013-12-26 | 2016-12-21 | Mitsubishi Tanabe Pharma Corp | Human anti-il-33 neutralization monoclonal antibody |
| EP3092253B1 (en) | 2014-01-10 | 2021-03-17 | AnaptysBio, Inc. | Antibodies directed against interleukin-33 (il-33) |
| IL315136A (en) * | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| WO2015130975A1 (en) | 2014-02-28 | 2015-09-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| NO2785538T3 (enExample) * | 2014-05-07 | 2018-08-04 | ||
| CN107109494B (zh) | 2014-11-10 | 2023-10-27 | 豪夫迈·罗氏有限公司 | Il-33介导型疾病的治疗方法和诊断方法 |
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| HUE053097T2 (hu) | 2015-03-31 | 2021-06-28 | Medimmune Ltd | Új IL33 forma, IL33 mutáltatott formái, ellenanyagok, vizsgálati eljárások és eljárások azok alkalmazására |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
-
2017
- 2017-11-29 TW TW106141530A patent/TWI784988B/zh active
- 2017-11-29 TW TW111142355A patent/TWI857389B/zh active
- 2017-11-30 NZ NZ754300A patent/NZ754300A/en unknown
- 2017-11-30 IL IL266770A patent/IL266770B2/en unknown
- 2017-11-30 BR BR112019010646A patent/BR112019010646A2/pt unknown
- 2017-11-30 CR CR20190311A patent/CR20190311A/es unknown
- 2017-11-30 KR KR1020257007692A patent/KR20250040088A/ko active Pending
- 2017-11-30 TN TNP/2019/000172A patent/TN2019000172A1/en unknown
- 2017-11-30 MA MA046954A patent/MA46954A/fr unknown
- 2017-11-30 WO PCT/US2017/064041 patent/WO2018102597A1/en not_active Ceased
- 2017-11-30 CA CA3044851A patent/CA3044851A1/en active Pending
- 2017-11-30 CN CN201780073449.2A patent/CN110167963B/zh active Active
- 2017-11-30 MX MX2019006177A patent/MX2019006177A/es unknown
- 2017-11-30 US US15/827,357 patent/US10815305B2/en active Active
- 2017-11-30 KR KR1020197015123A patent/KR102645242B1/ko active Active
- 2017-11-30 JP JP2019529476A patent/JP7132220B2/ja active Active
- 2017-11-30 EP EP17818689.6A patent/EP3548513A1/en active Pending
- 2017-11-30 UA UAA201907159A patent/UA127965C2/uk unknown
- 2017-11-30 AU AU2017367691A patent/AU2017367691B2/en active Active
- 2017-11-30 CN CN202410698813.6A patent/CN118662629A/zh active Pending
- 2017-11-30 KR KR1020247007290A patent/KR102780485B1/ko active Active
- 2017-11-30 MY MYPI2019002952A patent/MY200433A/en unknown
-
2019
- 2019-05-17 ZA ZA2019/03091A patent/ZA201903091B/en unknown
- 2019-05-20 PH PH12019501120A patent/PH12019501120A1/en unknown
- 2019-05-22 CO CONC2019/0005236A patent/CO2019005236A2/es unknown
- 2019-05-28 MX MX2023008368A patent/MX2023008368A/es unknown
- 2019-05-30 CL CL2019001475A patent/CL2019001475A1/es unknown
-
2020
- 2020-09-22 US US17/028,011 patent/US11866503B2/en active Active
-
2022
- 2022-08-24 JP JP2022132878A patent/JP7351989B2/ja active Active
-
2023
- 2023-09-13 JP JP2023148026A patent/JP2023175785A/ja active Pending
- 2023-11-29 US US18/523,048 patent/US20240209102A1/en active Pending
-
2024
- 2024-12-10 AU AU2024278257A patent/AU2024278257A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513404A5 (enExample) | ||
| JP2018533557A5 (enExample) | ||
| JP6830533B2 (ja) | 抗ｉｌ−３３抗体およびその使用 | |
| KR102307248B1 (ko) | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 | |
| JP2025131730A (ja) | Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法 | |
| ES2645368T3 (es) | Terapias para mejorar la función pulmonar | |
| Menzella et al. | Tailored therapy for severe asthma | |
| CN110167963A (zh) | 治疗发炎病况的方法 | |
| JP2016513644A5 (enExample) | ||
| JP2019531273A5 (enExample) | ||
| Grainge et al. | Targeted therapeutics for severe refractory asthma: monoclonal antibodies | |
| JP2023515260A (ja) | 抗ヒトインターロイキン－４受容体α抗体及びその調製方法並びに使用 | |
| RU2009120202A (ru) | Способы и композиции для лечения и мониторинга лечения связанных с il-13 расстройств | |
| JPWO2018191479A5 (enExample) | ||
| JP2025122028A (ja) | Ｉｌ－３３アンタゴニストを投与することにより喘息を治療するまたは予防するための方法 | |
| Hartley et al. | Severe asthma: novel advances in the pathogenesis and therapy | |
| CN115151568A (zh) | 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法 | |
| JP2025164767A (ja) | Ｉｌ－３３アンタゴニストを投与することによりｃｏｐｄを治療するための方法 | |
| JP7458790B2 (ja) | Ｉｌ－６阻害剤を含有する喘息の治療剤 | |
| US11156600B2 (en) | Assay for detecting TH1 and TH2 cell populations | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| Leung et al. | Emerging treatment options in severe asthma | |
| Seymour et al. | Intervention in Severe Eosinophilic | |
| WO2024146630A1 (zh) | 一种tslp抗体治疗哮喘的方法 | |
| JP2024529809A (ja) | アレルギー体質の個体群における抗ＩＬ－１３Ｒα１抗体またはその結合フラグメントを使用するアトピー性皮膚炎の処置 |